HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era

Human epidermal growth factor 2 (HER2)–low breast cancers, defined as tumors exhibiting a HER2 IHC score of 1+ or 2+ nonamplified, represent an emerging targetable entity in the clinicopathologic landscape of breast cancer. Traditionally considered as not sensitive to HER2-targeting agents, these tumors have shown to be susceptible to a new class of drugs, namely antibody-drug conjugates (ADCs). Indeed, the DESTINY-Breast04 phase 3 trial demonstrated the remarkable activity of trastuzumab deruxtecan for treating both hormone-receptor (HR)–positive and triple-negative metastatic breast cancers that show HER2-low expression, reshaping treatment algorithms for these diseases. Concomitantly, the TROPiCS-02 and the ASCENT phase 3 trials have established the role of the anti-Trop-2 ADC sacituzumab govitecan for HR-positive and triple-negative breast cancer, respectively. A careful evaluation of these trials, with their inclusion/exclusion criteria, efficacy and toxicity results, is required in order to understand how best to treat HER2-low metastatic breast cancer in the context of a rapidly evolving therapeutic landscape. The purpose of this narrative review is to recapitulate the available evidence on the use of ADCs in the treatment of HER2-low breast cancer, providing a perspective on their current role in clinical practice.

[1]  A. Bardia,et al.  LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) , 2022, Annals of Oncology.

[2]  A. Bardia,et al.  214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study , 2022, Annals of Oncology.

[3]  M. Piccart,et al.  Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer , 2022, npj Breast Cancer.

[4]  A. Bardia,et al.  Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Curigliano,et al.  Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. , 2022, Cancer discovery.

[6]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[7]  A. Bardia,et al.  168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study , 2022, Annals of Oncology.

[8]  G. Curigliano,et al.  Bystander effect of antibody–drug conjugates: fact or fiction? , 2022, Current Oncology Reports.

[9]  A. Bardia,et al.  Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies , 2021, CA: a cancer journal for clinicians.

[10]  Sung-Bae Kim,et al.  Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. , 2021, JAMA oncology.

[11]  S. Loi,et al.  ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Carey,et al.  Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  G. Curigliano,et al.  Antibody–Drug Conjugates for the Treatment of Breast Cancer , 2021, Cancers.

[14]  M. Piccart,et al.  Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. , 2021, The New England journal of medicine.

[15]  C. Criscitiello,et al.  Antibody–drug conjugates in solid tumors: a look into novel targets , 2021, Journal of Hematology & Oncology.

[16]  F. Cardoso,et al.  HER2-Low Breast Cancer: Pathological and Clinical Landscape. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[18]  S. Paik,et al.  NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[20]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Agatsuma,et al.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.

[22]  M. Shah,et al.  First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors , 2015, Clinical Cancer Research.

[23]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[24]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[25]  Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.